Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 3/20 | 0.64 |
| ▸ | MMP9 | P14780 | 3/20 | 0.64 |
| ▸ | MMP13 | P45452 | 3/20 | 0.64 |
| ▸ | MMP3 | P08254 | 2/20 | 0.64 |
| ▸ | MMP7 | P09237 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7685731 | 0.90 | MMP1 (0.58) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7685735 | 0.90 | MMP1 (0.58) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL12479656 | 0.81 | MMP1 (0.79) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7687390 | 0.80 | MMP1 (0.64) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7684949 | 0.79 | MMP1 (0.50) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7686447 | 0.79 | MMP1 (0.60) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7685520 | 0.79 | MMP1 (0.60) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7683726 | 0.78 | FKBP1A (0.50) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL7683722 | 0.78 | FKBP1A (0.50) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL1272867 | 0.78 | MMP1 (1.00) | MMP1MMP9MMP13MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128269-A1 | Substituted heterocyclic compounds for treating multidrug resistance | ABCC1, ABCB1, ABCG2 | MMP1 3802/4885MMP9 2228/4885MMP13 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.